An update on epidermal growth factor receptor inhibitors. Review uri icon

Overview

abstract

  • The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from cell growth and proliferation to cell death. Dysregulation of the EGFR signal transduction pathway has been implicated in tumorigenesis and cancer progression, making it a clinically relevant target for novel anticancer treatments. This paper reviews recent progress in the development of cancer therapies that are directed toward particular aspects of the extracellular and intracellular domains of EGFR. Promising new compounds in the advanced stages of clinical testing are emphasized.

publication date

  • January 1, 2002

Research

keywords

  • Antineoplastic Agents
  • ErbB Receptors
  • Neoplasms
  • Signal Transduction

Identity

Scopus Document Identifier

  • 0036134210

Digital Object Identifier (DOI)

  • 10.1007/s11912-002-0047-6

PubMed ID

  • 11734113

Additional Document Info

volume

  • 4

issue

  • 1